330 related articles for article (PubMed ID: 33011930)
1. Prevention of anthracycline-induced cardiotoxicity: a systematic review and meta-analysis.
Caspani F; Tralongo AC; Campiotti L; Asteggiano R; Guasti L; Squizzato A
Intern Emerg Med; 2021 Mar; 16(2):477-486. PubMed ID: 33011930
[TBL] [Abstract][Full Text] [Related]
2. Cardioprotective role of β-blockers and angiotensin antagonists in early-onset anthracyclines-induced cardiotoxicity in adult patients: a systematic review and meta-analysis.
Yun S; Vincelette ND; Abraham I
Postgrad Med J; 2015 Nov; 91(1081):627-33. PubMed ID: 26399268
[TBL] [Abstract][Full Text] [Related]
3. Beta-blockers for the primary prevention of anthracycline-induced cardiotoxicity: a meta-analysis of randomized controlled trials.
Ma Y; Bai F; Qin F; Li J; Liu N; Li D; Li T; Xie H; Liu D; Zhou S; Liu Q
BMC Pharmacol Toxicol; 2019 Apr; 20(1):18. PubMed ID: 31023386
[TBL] [Abstract][Full Text] [Related]
4. A systematic review and meta-analysis of beta-blockers and renin-angiotensin system inhibitors for preventing left ventricular dysfunction due to anthracyclines or trastuzumab in patients with breast cancer.
Lewinter C; Nielsen TH; Edfors LR; Linde C; Bland JM; LeWinter M; Cleland JGF; Køber L; Braunschweig F; Mansson-Broberg A
Eur Heart J; 2022 Jul; 43(27):2562-2569. PubMed ID: 34951629
[TBL] [Abstract][Full Text] [Related]
5. Role of cardioprotective agents on chemotherapy-induced heart failure: A systematic review and network meta-analysis of randomized controlled trials.
Li X; Li Y; Zhang T; Xiong X; Liu N; Pang B; Ruan Y; Gao Y; Shang H; Xing Y
Pharmacol Res; 2020 Jan; 151():104577. PubMed ID: 31790821
[TBL] [Abstract][Full Text] [Related]
6. Meta-Analysis Comparing Usefulness of Beta Blockers to Preserve Left Ventricular Function During Anthracycline Therapy.
Shah P; Garris R; Abboud R; Vasudev R; Patel H; Doshi R; Shamoon F; Bikkina M
Am J Cardiol; 2019 Sep; 124(5):789-794. PubMed ID: 31307662
[TBL] [Abstract][Full Text] [Related]
7. Heart failure from cancer therapy: can we prevent it?
Totzeck M; Mincu RI; Heusch G; Rassaf T
ESC Heart Fail; 2019 Aug; 6(4):856-862. PubMed ID: 31297946
[TBL] [Abstract][Full Text] [Related]
8. Renin-angiotensin System Antagonists and Beta-blockers in Prevention of Anthracycline Cardiotoxicity: a Systematic Review and Meta-analysis.
Avila MS; Siqueira SRR; Waldeck L; Ayub-Ferreira SM; Takx R; Bittencourt MS; Bocchi EA
Arq Bras Cardiol; 2023; 120(5):e20220298. PubMed ID: 37255127
[TBL] [Abstract][Full Text] [Related]
9. Protective Effects of ACEI/ARB on Left Ventricular Function in Anthracycline-Induced Chronic Cardiotoxicity: A Meta-Analysis of Randomized Controlled Trials.
Lin H; Liang G; Wu Y; Chen L
Cardiology; 2021; 146(4):469-480. PubMed ID: 33946067
[TBL] [Abstract][Full Text] [Related]
10. Cardiotoxic Effect of Modern Anthracycline Dosing on Left Ventricular Ejection Fraction: A Systematic Review and Meta-Analysis of Placebo Arms From Randomized Controlled Trials.
Jeyaprakash P; Sangha S; Ellenberger K; Sivapathan S; Pathan F; Negishi K
J Am Heart Assoc; 2021 Mar; 10(6):e018802. PubMed ID: 33660514
[TBL] [Abstract][Full Text] [Related]
11. Beta-Blockers for Primary Prevention of Anthracycline-Induced Cardiac Toxicity: An Updated Meta-Analysis of Randomized Clinical Trials.
Attar A; Behnagh AK; Hosseini M; Amanollahi F; Shafiekhani P; Kabir A
Cardiovasc Ther; 2022; 2022():8367444. PubMed ID: 36687509
[TBL] [Abstract][Full Text] [Related]
12. Cardioprotective Effects and Duration of Beta Blocker Therapy in Anthracycline-Treated Patients: A Systematic Review and Meta-analysis.
Xu L; Long Y; Tang X; Zhang N
Cardiovasc Toxicol; 2020 Feb; 20(1):11-19. PubMed ID: 31832905
[TBL] [Abstract][Full Text] [Related]
13. Protective role of beta-blockers in chemotherapy-induced cardiotoxicity-a systematic review and meta-analysis of carvedilol.
Huang S; Zhao Q; Yang ZG; Diao KY; He Y; Shi K; Shen MT; Fu H; Guo YK
Heart Fail Rev; 2019 May; 24(3):325-333. PubMed ID: 30523513
[TBL] [Abstract][Full Text] [Related]
14. Statins as preventive therapy for anthracycline cardiotoxicity: a meta-analysis of randomized controlled trials.
D'Amario D; Laborante R; Bianchini E; Galli M; Ciliberti G; Mennuni M; Patti G
Int J Cardiol; 2023 Nov; 391():131219. PubMed ID: 37527752
[TBL] [Abstract][Full Text] [Related]
15. Cardioprotective interventions for cancer patients receiving anthracyclines.
van Dalen EC; Caron HN; Dickinson HO; Kremer LC
Cochrane Database Syst Rev; 2005 Jan; (1):CD003917. PubMed ID: 15674919
[TBL] [Abstract][Full Text] [Related]
16. ACEI/ARB and beta-blocker therapies for preventing cardiotoxicity of antineoplastic agents in breast cancer: a systematic review and meta-analysis.
Gao Y; Wang R; Jiang J; Hu Y; Li H; Wang Y
Heart Fail Rev; 2023 Nov; 28(6):1405-1415. PubMed ID: 37414918
[TBL] [Abstract][Full Text] [Related]
17. Anthracycline-associated cardiotoxicity in adults: systematic review on the cardioprotective role of beta-blockers.
Barbosa RR; Bourguignon TB; Torres LD; Arruda LS; Jacques TM; Serpa RG; Calil OA; Barbosa LFM
Rev Assoc Med Bras (1992); 2018 Aug; 64(8):745-754. PubMed ID: 30673046
[TBL] [Abstract][Full Text] [Related]
18. The Preventive Role of Angiotensin Converting Enzyme Inhibitors/Angiotensin-II Receptor Blockers and β-Adrenergic Blockers in Anthracycline- and Trastuzumab-Induced Cardiotoxicity.
Blanter JB; Frishman WH
Cardiol Rev; 2019; 27(5):256-259. PubMed ID: 31008768
[TBL] [Abstract][Full Text] [Related]
19. Preventive use of carvedilol for anthracycline-induced cardiotoxicity: a systematic review and meta-analysis of randomized controlled trials.
Zhan T; Daniyal M; Li J; Mao Y
Herz; 2020 Dec; 45(Suppl 1):1-14. PubMed ID: 30656389
[TBL] [Abstract][Full Text] [Related]
20. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials.
Smith LA; Cornelius VR; Plummer CJ; Levitt G; Verrill M; Canney P; Jones A
BMC Cancer; 2010 Jun; 10():337. PubMed ID: 20587042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
